Guardant Health (NASDAQ:GH) Posts Earnings Results, Beats Expectations By $0.08 EPS

Key Points

• Guardant Health reported a quarterly earnings per share (EPS) of ($0.44), exceeding analysts' expectations by $0.08, with revenues of $232.09 million, up 31% year-over-year.
• Several brokerages have raised their price targets for the stock, with UBS Group increasing it from $65.00 to $70.00, reflecting strong investor sentiment.
• Insider trading activity has shown a decline, with CEO Amirali Talasaz selling 100,000 shares, decreasing his stake in the company by 4.83%.

Guardant Health (NASDAQ:GH - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08, Briefing.com reports. The business had revenue of $232.09 million during the quarter, compared to analysts' expectations of $211.19 million. Guardant Health's revenue for the quarter was up 31.0% on a year-over-year basis. During the same period last year, the company posted ($0.84) EPS. Guardant Health updated its FY 2025 guidance to EPS.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $40.98 on Friday. Guardant Health has a 1 year low of $20.14 and a 1 year high of $53.42. The company has a market cap of $5.08 billion, a P/E ratio of -12.23 and a beta of 1.44. The stock's fifty day moving average price is $47.14 and its 200-day moving average price is $44.87.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GH. UBS Group increased their target price on Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. TD Securities increased their price objective on Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Piper Sandler restated an "overweight" rating and set a $60.00 target price (up previously from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. Scotiabank upped their target price on shares of Guardant Health from $57.00 to $60.00 and gave the stock a "sector outperform" rating in a research report on Thursday. Finally, Evercore ISI raised shares of Guardant Health to a "strong-buy" rating in a research note on Monday, July 14th. Nineteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $54.95.

Insider Buying and Selling

In other Guardant Health news, CEO Amirali Talasaz sold 100,000 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the transaction, the chief executive officer owned 1,971,830 shares in the company, valued at approximately $100,326,710.40. This represents a 4.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Meghan V. Joyce sold 3,337 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $47.22, for a total transaction of $157,573.14. Following the sale, the director directly owned 11,150 shares in the company, valued at approximately $526,503. The trade was a 23.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold 235,516 shares of company stock worth $11,848,754 in the last three months. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Guardant Health

A hedge fund recently raised its stake in Guardant Health stock. AQR Capital Management LLC boosted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 56.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 71,534 shares of the company's stock after buying an additional 25,831 shares during the quarter. AQR Capital Management LLC owned approximately 0.06% of Guardant Health worth $3,012,000 at the end of the most recent quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.